Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Swedish Orphan Biovitrum AB ( (SE:SOBI) ) is now available.
Swedish Orphan Biovitrum AB (Sobi) announced an increase in its total number of common shares and votes to 357,412,837 as of September 30, 2025, following the conversion of 1,412,788 class C shares to common shares. This change is part of Sobi’s efforts to fulfill commitments under its long-term incentive programs, potentially impacting its market operations and stakeholder interests.
The most recent analyst rating on (SE:SOBI) stock is a Hold with a SEK302.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.
More about Swedish Orphan Biovitrum AB
Sobi is a global biopharma company focused on breakthrough innovations for rare diseases, employing approximately 1,900 people across various regions including Europe, North America, the Middle East, Asia, and Australia. In 2024, the company reported a revenue of SEK 26 billion and is listed on Nasdaq Stockholm.
Average Trading Volume: 279,639
Technical Sentiment Signal: Hold
Current Market Cap: SEK93.63B
See more insights into SOBI stock on TipRanks’ Stock Analysis page.